Ponatinib (hydrochloride)
Product Specifications
UNSPSC Description
Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively[1].
Target Antigen
Autophagy; Bcr-Abl; FGFR; PDGFR; Src; VEGFR
Type
Reference compound
Related Pathways
Autophagy;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/ponatinib-hydrochloride.html
Purity
99.55
Solubility
DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
O=C(C1=CC=C(C)C(C#CC2=CN=C3C=CC=NN23)=C1)NC4=CC=C(CN5CCN(CC5)C)C(C(F)(F)F)=C4.Cl
Molecular Weight
569.02
References & Citations
[1]O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412.|[2]Gover-Proaktor A, et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma. 2017 Jun;58(6):1455-1467.|[3]Hong YP, et al. Effects of Castanospermine on Inflammatory Response in a Rat Model of Experimental Severe Acute Pancreatitis. Arch Med Res. 2016 Aug;47(6):436-445.Biomaterials. 16 September 2022.|Acta Pharm Sin B. 2023 Oct;13(10):4253-4272.|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Biochem Pharmacol. 2021 Jul 30;114710.|Biomed Pharmacother. 2024 Oct 16:180:117569.|Biomolecules. 2022 Jun 11;12(6):819.|bioRxiv. 2024 Apr 21.|Cancer Discov. 2021 Jan;11(1):126-141.|Clin Chim Acta. 2018 May;480:180-185. |Commun Biol. 2024 Jul 10;7(1):843.|Eur J Pharmacol. 2020 Dec 15;889:173292.|Exp Hematol. 2014 May;42(5):369-379.e3.|Fundam Clin Pharmacol. 2021 Feb 1.|Harvard Medical School LINCS LIBRARY|Heliyon. 2024 Sep 28;10(19):e38637.|J Chem Eng Data. 2024 Jun 10.|J Ethnopharmacol. 2023 Dec 28, 117669.|J Ethnopharmacol. 2023 Feb 17;116275.|J Med Chem. 2019 May 23;62(10):5006-5024. |J Med Chem. 2024 Nov 28;67(22):20571-20579.|Leuk Res. 2016 Jun;45:24-32. |Neurosci Bull. 2020 Mar;36(3):263-276.|Pharmaceuticals. 2022, 15(9), 1073.|Pharmacogn Mag. 2023 Jul 20.|PLoS One. 2021 Sep 30;16(9):e0258140.|PLoS One. 2022 Feb 14;17(2):e0263822.|Research Square Preprint. 2021 May.|Research Square Print. 2023 Mar 23.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Target Oncol. 2020 Oct;15(5):659-671.|Technical University of Munich. 24.01.2018.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-108766/Ponatinib-hydrochloride-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-108766/Ponatinib-hydrochloride-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
1114544-31-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6383450-01 0.1 mL
KATNA1 (Katanin p60 ATPase-containing Subunit A1, Katanin p60 Subunit A1, p60 Katanin) (MaxLight 550)
Ask
View Details MBS6383450-02 5x 0.1 mL
KATNA1 (Katanin p60 ATPase-containing Subunit A1, Katanin p60 Subunit A1, p60 Katanin) (MaxLight 550)
Ask
View Details 